Study suggests potential link between Ozempic and blindness

In a recent study conducted by researchers at Mass General Brigham, patients who took the commonly prescribed diabetes and weight-loss drugs Ozempic and Wegovy were found to have a higher risk of developing a rare optic nerve condition called NAION, which can lead to blindness. The study highlighted an association between the use of semaglutide, the active ingredient in these medications, and the development of NAION. However, the researchers noted that more evidence is needed to establish a definitive cause-and-effect relationship. The World Health Organization (WHO) has issued a global alert following these findings, cautioning patients to consider the potential risks associated with these medications. While the drugs' marketing labels approved by the Food and Drug Administration do not list NAION as a known side effect, the study revealed a concerning trend among patients prescribed semaglutide compared to those on other diabetes or weight loss medications. Dr. Andrew Lee, a clinical spokesperson for the American Academy of Ophthalmology, emphasized the need for further research to confirm the link between semaglutide and vision problems. The study's results, based on a subset of patients with diabetes, obesity, or overweight, showed a higher incidence of NAION among those prescribed semaglutide compared to other drugs. The researchers stressed the importance of discussing these findings with healthcare providers, especially for patients with existing optic nerve issues. The study's authors underscored the significance of their findings but acknowledged the need for more extensive studies involving a larger and more diverse population. The potential risks associated with weight loss medications like semaglutide have raised concerns among healthcare professionals, prompting discussions about the safety and efficacy of these drugs. As the debate continues, patients are advised to exercise caution and consult with their doctors regarding the use of these medications, particularly if they have pre-existing visual impairments or optic nerve conditions.